HomeEXECUTIVESJesse Neri Named Senior Vice President at Finance at Rockwell Medical

Jesse Neri Named Senior Vice President at Finance at Rockwell Medical

Jesse Neri has joined the Company as Senior Vice President, Finance. Mr. Neri will oversee all aspects of Rockwell Medical’s finance organization.

Jesse Neri has over 20 years’ experience leading finance functions at both public and private companies. Prior to joining Rockwell Medical, he was the head of finance at Hemavant Sciences, a clinical stage biopharmaceutical company developing therapeutics to improve the lives of patients with blood disorders and hematological malignancies. Previously, Mr. Neri served as Senior Vice President of Finance at Zyla Life Sciences, a public pharmaceutical company with annual revenue of $80 million. As a member of the senior management team, Mr. Neri was responsible for all aspects of its finance organization including SEC reporting, audit, controllership, and strategic planning. While at Zyla, he played a pivotal role in multiple product acquisitions, financings, commercial product launches and regulatory approvals, along with Zyla’s acquisition by Assertio Therapeutics in May 2020. Prior to Zyla, Mr. Neri served as Vice President of Financial Planning and Analysis at Symphony Health Solutions, a private equity-backed market research company with revenues over $200 million. Mr. Neri received a B.S., Business Administration of Finance from Villanova University and an M.B.A. from Drexel University LeBow School of Business.

“Jesse’s extensive experience leading finance organizations within revenue-generating, growth-oriented healthcare businesses will be valuable to Rockwell Medical as we contemplate various avenues of expansion and growth,” said Mark Strobeck, Ph.D., President and CEO at Rockwell Medical. “Additionally, Jesse’s expertise will enhance our ability to continue strengthening our financial and operating infrastructure while advancing our ability to meet our strategic objectives.”

“I am thrilled to be joining Rockwell Medical as its new head of finance at such an exciting time in the Company’s history,” said Jessee Neri. “Rockwell Medical continues to improve its balance sheet and expand its leadership position in the renal healthcare space. I am excited to be part of a team that is focused on innovative, long-term growth strategies that have the potential to positively impact patients and shareholders around the globe.”

The Compensation Committee of the Company’s Board of Directors approved the grant of stock options to purchase 75,000 shares of the Company’s common stock to Mr. Neri (the “Inducement Grant”) on October 16, 2023 (the “Grant Date”). The Inducement Grant has been granted outside of the Company’s 2018 Long Term Incentive Plan (“Plan”) but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to Mr. Neri entering into employment with Rockwell Medical in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share that is equal to the closing price of the Company’s common stock on the Grant Date. The Inducement Grant will vest 25% on each of the first four anniversaries of the Grant Date until fully vested, subject to Mr. Neri’s continued employment through the applicable vesting dates.

Rockwell Medical, Inc. is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Dr Charles R Gordon was the founding Chairman of the Board for Baylor Scott & White's Texas Spine & Joint Hospital. Over the years the hospital has grown, and majority interest of the hospital was sold to Baylor Scott & White and United Surgical Partners International (USPI).
"We are excited to welcome Jeff Anderson to Nutjobs as our new CEO. His broad experience and tactical leadership will be instrumental in executing against our vision to provide innovative, sustainable solutions to our customers," said Paul Kephart, Co-Founder, Chief Technology Officer and Chairperson of the Nutjobs Board.
Potrero Medical believes that this voluntary reorganization will bolster its finances and facilitate its ongoing focus on elevating patient care.
Dr John Parker will work closely with PeriGen's client base to optimize use of the company's analytics for patient care and research. He will also be instrumental in informing product development and regulatory affairs as PeriGen continues to expand its product suite and associated services.
“We’re delighted to welcome Gerald and Hannah to the PrecisionLife team at a time when our deep disease insights and patient stratification biomarkers are finding important new markets and bringing precision approaches to the early, more accurate diagnosis and care of patients with complex chronic diseases,” said Dr Steve Gardner, PrecisionLife CEO.

By using this website you agree to accept Medical Device News Magazine Privacy Policy